Real world study on efficacy and safety of surufatinib in advanced solid tumors evaluation

Abstract Surufatinib is a novel, China-developed small-molecule tyrosine kinase inhibitor that demonstrates high selectivity for VEGFR, FGFR1, and CSF1R. Surufatinib has been approved for the treatment of neuroendcrine tumors, including pancreatic neuroendocrine tumors (PNEN) and non-pancreatic neur...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Hui-Ping Yan, Hong-Yang Zhao, An-Chen Qiu, Xiao-Chen Chen, Ke Chen, Zhe-Ling Chen, Si-Fu Yang
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Portfolio 2025-05-01
Schriftenreihe:	Scientific Reports
Schlagworte:	Surufatinib Solid tumor Vascular endothelial growth factor receptor Pancreatic neuroendocrine tumor Non-pancreatic neuroendocrine tumor
Online-Zugang:	https://doi.org/10.1038/s41598-025-00974-8
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!